Hi-Tech Pharmacal Co. (HITK) Misses Q1 EPS by 24c; Sales Light

Hi-Tech Pharmacal Co. (NASDAQ: HITK) reported Q1 EPS of $0.44, $0.24 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $52 million versus the consensus estimate of $57.6 million.

NOTE: Shares were halted.

For earnings history and earnings-related data on Hi-Tech Pharmacal Co. (HITK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance
• Avangrid (AGR) Tops Q1 EPS by 19c